NASDAQ:PBLS Parabilis Medicines (PBLS) Stock Price, News & Analysis $29.58 0.00 (0.00%) As of 07/2/2026 04:00 PM Eastern Add Share Share Stock Analysis Stock AnalysisChartInsider TradesSEC FilingsTrendsBuy This Stock About Parabilis Medicines Stock (NASDAQ:PBLS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Parabilis Medicines alerts:Sign Up Key Stats Today's Range$27.41▼$29.6150-Day Range N/A52-Week Range$24.51▼$34.47Volume302,520 shsAverage Volume1.04 million shsMarket Capitalization$3.49 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingBuy Company Overview Read More Parabilis Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScorePBLS MarketRank™: Parabilis Medicines scored higher than 70% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingBuy Consensus RatingParabilis Medicines has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageParabilis Medicines has only been the subject of 1 research reports in the past 90 days.Read more about Parabilis Medicines' stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.95% of the float of Parabilis Medicines has been sold short.Short Interest Ratio / Days to CoverParabilis Medicines has a short interest ratio ("days to cover") of 1.33, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Parabilis Medicines has recently increased by 100.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldParabilis Medicines does not currently pay a dividend.Dividend GrowthParabilis Medicines does not have a long track record of dividend growth. News and Social Media4.5 / 5News Sentiment1.15 News SentimentParabilis Medicines has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Parabilis Medicines this week, compared to 2 articles on an average week.Search Interest6 people have searched for PBLS on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows1 people have added Parabilis Medicines to their MarketBeat watchlist in the last 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Parabilis Medicines in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $10,723,528.00 in company stock, which represents 0.3068% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Parabilis Medicines insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,723,528.00 in company stock and sold $0.00 in company stock.Percentage Held by InstitutionsParabilis Medicines has minimal institutional ownership at this time.Read more about Parabilis Medicines' insider trading history. Receive PBLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Parabilis Medicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PBLS Stock News HeadlinesPBLS Parabilis Medicines, Inc.July 2, 2026 | seekingalpha.comParabilis Medicines (NASDAQ:PBLS) Major Shareholder Guy Levy Acquires 500,000 Shares of StockJune 30, 2026 | americanbankingnews.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing. | Profits Run (Ad)Guy Levy Acquires 500,000 Shares of Parabilis Medicines (NASDAQ:PBLS) StockJune 30, 2026 | insidertrades.comThis Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already InvestedJune 27, 2026 | fool.comFresh Off IPO, A Director Buys $474,000 of Parabilis Medicines Stock. Is PBLS a Buy?June 20, 2026 | fool.comInsider Buying: Parabilis Medicines (NASDAQ:PBLS) Director Acquires 8,435 Shares of StockJune 17, 2026 | insidertrades.comParabilis Medicines (PBLS) Stock Valuation After Recent 10% Single Day DeclineJune 15, 2026 | finance.yahoo.comSee More Headlines PBLS Stock Analysis - Frequently Asked Questions How have PBLS shares performed this year? Parabilis Medicines' stock was trading at $31.60 on June 10, 2026. Since then, PBLS shares have decreased by 6.4% and is now trading at $29.58. When did Parabilis Medicines IPO? Parabilis Medicines (PBLS) raised $603 million in an IPO on Wednesday, June 10th 2026. The company issued 33,500,000 shares at a price of $17.00-$19.00 per share. When does the company's quiet period expire? Parabilis Medicines's quiet period expires on Monday, July 20th. Parabilis Medicines had issued 33,500,000 shares in its IPO on June 10th. The total size of the offering was $670,000,000 based on an initial share price of $20.00. During the company's quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company. How do I buy shares of Parabilis Medicines? Shares of PBLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:PBLS CIK1657677 WebN/A PhoneN/AFaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares118,146,000Free FloatN/AMarket Cap$3.49 billion OptionableN/A BetaN/A 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:PBLS) was last updated on 7/6/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredBuy the “unseen winner of the AI race” before July 22Marc Chaikin - the analyst who called Nvidia before a 45,000% surge - says one overlooked AI stock could split...Chaikin Analytics | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredThey proved it worked in '76. Then buried it.In 1976, Chevron, Unocal, and Texaco each confirmed the same energy technology worked - no fuel costs, no carb...Behind the Markets | Sponsored**MARKET CRASH WARNING**A former advisor to the Pentagon and CIA is warning that an 80% Dow drop could arrive within days - and names ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Parabilis Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Parabilis Medicines With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.